{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:20:44Z","timestamp":1781536844461,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","award":["8083"],"award-info":[{"award-number":["8083"]}],"id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic macular edema (DME) is a leading cause of visual impairment in patients with diabetes. Intravitreal anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for DME, with aflibercept having demonstrated favorable outcomes in comparative studies. However, data on the efficacy of anti-VEGF therapy in vitrectomized eyes are inconclusive. Corticosteroids, specifically dexamethasone (DEX) implant, may be used for refractory cases. This study aimed to evaluate the efficacy of intravitreal aflibercept (IVA) in patients with DME with or without prior pars plana vitrectomy (PPV) and to evaluate the outcomes of DEX implantation in refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective single-center study included 46 eyes with center-involved DME. Eyes were divided into PPV and intact vitreous body (non-PPV) groups. All patients received IVA injections following the DRCR.net Protocol T. After six monthly injections, eyes refractory to IVA treatment were switched to DEX implant (refractory group). In the non-refractory group IVA injections were administered as needed (PRN) until month 12. The best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) were measured at baseline; at 1 week; monthly through month 6 in all eyes; monthly through month 12 in the non-refractory group; and at 2 months after DEX implantation in the refractory group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 23 eyes each in the PPV and non-PPV groups. Overall, 13 (28.3%) eyes were refractory to IVA (8 PPV, 5 non-PPV;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). The median number of IVA injections among PPV and non-PPV eyes in the non-refractory group over 12 months showed no significant difference (PPV: 10; non-PPV: 9.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Both groups showed significant improvement in BCVA (PPV: +7.0 letters; non-PPV: +11.1 letters; both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and CSFT (PPV: \u2212\u2009182.5\u00a0\u03bcm; non-PPV: \u2212\u2009190.4\u00a0\u03bcm; both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) at 12 months. In refractory cases, DEX implantation resulted in a significant CSFT reduction (\u2013259.1\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) but not BCVA improvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVA is effective for DME regardless of vitreous status, with similar efficacy and treatment frequency in vitrectomized and non-vitrectomized eyes. DEX implantation produces anatomical benefits in IVA-refractory cases, although visual gains are limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00778-y","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:33:10Z","timestamp":1765290790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of aflibercept in vitrectomized vs. non-vitrectomized eyes with diabetic macular edema: a prospective study"],"prefix":"10.1186","volume":"12","author":[{"given":"G\u00e9za","family":"Thury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Baranyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"R\u00e1rosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeka","family":"H\u00e9jja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"e52676","DOI":"10.7759\/cureus.52676","volume":"16","author":"AA Cheema","year":"2024","unstructured":"Cheema AA, Cheema HR. Diabetic macular edema management: A review of Anti-Vascular endothelial growth factor (VEGF) therapies. Cureus. 2024;16:e52676. https:\/\/doi.org\/10.7759\/cureus.52676.","journal-title":"Cureus"},{"key":"778_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222. https:\/\/doi.org\/10.1159\/000458539.","journal-title":"Ophthalmologica"},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.5301\/ejo.5001053","volume":"27","author":"T Avitabile","year":"2017","unstructured":"Avitabile T, Azzolini C, Bandello F, Boscia F, De Falco S, Fornasari D, et al. Aflibercept in the treatment of diabetic macular edema: A review and consensus paper. Eur J Ophthalmol. 2017;27:627\u201339. https:\/\/doi.org\/10.5301\/ejo.5001053.","journal-title":"Eur J Ophthalmol"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with Aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: A randomized clinical trial. JAMA. 2019;321:1880\u201394. https:\/\/doi.org\/10.1001\/jama.2019.5790.","journal-title":"JAMA"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or Ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28:636\u201343. https:\/\/doi.org\/10.1097\/ICU.0000000000000424.","journal-title":"Curr Opin Ophthalmol"},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.006.","journal-title":"Ophthalmology"},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IAE.0000000000002196","volume":"39","author":"M Iglicki","year":"2019","unstructured":"Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES, et al. The international retina group Real-Life 24-Month multicenter study. The IRGREL-DEX study. Retina. 2019;39:44\u201351. https:\/\/doi.org\/10.1097\/IAE.0000000000002196.","journal-title":"Retina"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","volume":"67","author":"K Madjedi","year":"2022","unstructured":"Madjedi K, Pereira A, Ballios BG, Arjmand P, Kertes PJ, Brent M, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: A systematic review. Surv Ophthalmol. 2022;67:1364\u201372. https:\/\/doi.org\/10.1016\/j.survophthal.2022.04.001.","journal-title":"Surv Ophthalmol"},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or Ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa1414264.","journal-title":"N Engl J Med"},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-Year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology"},{"key":"778_CR11","doi-asserted-by":"crossref","unstructured":"Wong HL, Fung NSK, Kwok AKH. Brolucizumab and faricimab as new treatment options for diabetic macular edema: perspective. Hong Kong Journal of Ophthalmology [Internet]. 2022 [cited 2025 Oct 2];26. https:\/\/hkjo.hk\/index.php\/hkjo\/article\/view\/327. Accessed 2 Oct 2025.","DOI":"10.12809\/hkjo-v26n2-327"},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal Aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","journal-title":"Lancet"},{"key":"778_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41433-019-0615-8","volume":"34","author":"I Pearce","year":"2020","unstructured":"Pearce I, Bailey C, Fletcher E, Ghanchi F, Rennie C, Santiago C, et al. Translating evidence into practice: recommendations by a UK expert panel on the use of Aflibercept in diabetic macular oedema. Eye (Lond). 2020;34:969\u201381. https:\/\/doi.org\/10.1038\/s41433-019-0615-8.","journal-title":"Eye (Lond)"},{"key":"778_CR14","first-page":"402","volume":"119","author":"H Nakashizuka","year":"2015","unstructured":"Nakashizuka H, Shimada H, Hattori T, Yamamoto A, Tanaka K, Kitagawa Y, et al. [Incidence of postoperative retinal detachment after 25-gauge vitrectomy for macular Diseases]. Nippon Ganka Gakkai Zasshi. 2015;119:402\u20139.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"778_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ophtha.2017.01.001","volume":"124","author":"MD McLaughlin","year":"2017","unstructured":"McLaughlin MD, Hwang JC. Trends in vitreoretinal procedures for medicare Beneficiaries, 2000 to 2014. Ophthalmology. 2017;124:667\u201373. https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.001.","journal-title":"Ophthalmology"},{"key":"778_CR16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41433-021-01647-2","volume":"36","author":"HA Madi","year":"2022","unstructured":"Madi HA, Keller J. Increasing frequency of hospital admissions for retinal detachment and vitreo-retinal surgery in England 2000\u20132018. Eye (Lond). 2022;36:1610\u20134. https:\/\/doi.org\/10.1038\/s41433-021-01647-2.","journal-title":"Eye (Lond)"},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","volume":"13","author":"M Edington","year":"2017","unstructured":"Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. 2017;13:1217\u201324. https:\/\/doi.org\/10.1080\/17425255.2017.1404987.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10792-017-0462-1","volume":"38","author":"Y-Y Chen","year":"2018","unstructured":"Chen Y-Y, Chen P-Y, Chen F-T, Chen Y-J, Wang J-K. Comparison of efficacy of intravitreal Ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema. Int Ophthalmol. 2018;38:293\u20139. https:\/\/doi.org\/10.1007\/s10792-017-0462-1.","journal-title":"Int Ophthalmol"},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2147\/OPTH.S304030","volume":"15","author":"THC Tran","year":"2021","unstructured":"Tran THC, Erginay A, Verdun S, Fourmaux E, Le Rouic J-F, Uzzan J, et al. One-Year outcome of Aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema. Clin Ophthalmol. 2021;15:1971\u20138. https:\/\/doi.org\/10.2147\/OPTH.S304030.","journal-title":"Clin Ophthalmol"},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1097\/IAE.0000000000000617","volume":"35","author":"SB Bressler","year":"2015","unstructured":"Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY, et al. Retina. 2015;35:2516\u201328. https:\/\/doi.org\/10.1097\/IAE.0000000000000617.","journal-title":"Retina"},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, Patel LG, Ammar MJ, Hsu J, et al. Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting. Am J Ophthalmol. 2021;232:90\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.030.","journal-title":"Am J Ophthalmol"},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-Vascular endothelial growth factor therapy: an exploratory analysis of the protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137:382\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6786.","journal-title":"JAMA Ophthalmol"},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40942-023-00453-0","volume":"9","author":"RL Gurung","year":"2023","unstructured":"Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitreous. 2023;9:23. https:\/\/doi.org\/10.1186\/s40942-023-00453-0.","journal-title":"Int J Retina Vitreous"},{"key":"778_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/joco.joco_308_21","volume":"34","author":"S Santhakumaran","year":"2022","unstructured":"Santhakumaran S, Salimi A, Brunetti VC, Galic J. Efficacy and safety of Aflibercept therapy for diabetic macular edema: A systematic review and Meta-Analysis. J Curr Ophthalmol. 2022;34:133\u201347. https:\/\/doi.org\/10.4103\/joco.joco_308_21.","journal-title":"J Curr Ophthalmol"},{"key":"778_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/OPTH.S154421","volume":"12","author":"R Campos Polo","year":"2018","unstructured":"Campos Polo R, Rubio S\u00e1nchez C, Garc\u00eda Guisado DM, D\u00edaz Luque MJ. Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. Clin Ophthalmol. 2018;12:99\u2013104. https:\/\/doi.org\/10.2147\/OPTH.S154421.","journal-title":"Clin Ophthalmol"},{"key":"778_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and Long-Term responses to Anti-Vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2016.09.012.","journal-title":"Am J Ophthalmol"},{"key":"778_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","volume":"55","author":"C Busch","year":"2018","unstructured":"Busch C, Zur D, Fraser-Bell S, La\u00edns I, Santos AR, Lupidi M, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55:789\u201396. https:\/\/doi.org\/10.1007\/s00592-018-1151-x.","journal-title":"Acta Diabetol"},{"key":"778_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jfo.2019.12.006","volume":"43","author":"A Couturier","year":"2020","unstructured":"Couturier A, Giocanti-Auregan A, Massin P. Les switchs de traitement Dans l\u2019\u0153d\u00e8me maculaire diab\u00e9tique: revue de La litt\u00e9rature et algorithme de prise En charge. J Fran\u00e7ais d\u2019Ophtalmologie. 2020;43:710\u20137. https:\/\/doi.org\/10.1016\/j.jfo.2019.12.006.","journal-title":"J Fran\u00e7ais d\u2019Ophtalmologie"},{"key":"778_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","volume":"31","author":"DS Boyer","year":"2011","unstructured":"Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li X-Y, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915\u201323. https:\/\/doi.org\/10.1097\/IAE.0b013e318206d18c.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00778-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:02:05Z","timestamp":1768359725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00778-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the University of Szeged reviewed and approved the trial (Protocol no. NH_SiOP-001, Reference no. 168\/2022-SZTE RKEB). This study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}